Liponex to Present CRD5 Development Update at the 16th International Symposium for Drugs Affecting Lipid Metabolism

    OTTAWA, Sept. 27 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," announced today that the
company will present a CRD5 development update at the 16th International
Symposium for Drugs Affecting Lipid Metabolism (DALM). Dr. Daniel Sparks,
founder and Chief Scientific Officer of Liponex, will give the presentation
entitled, "Clinical Development of a Novel HDL Therapeutic" on October 5, 2007
in New York City.
    "This prestigious international conference provides us with the
opportunity to present an update on the clinical development status of our
novel HDL therapeutic, CRD5. The company will highlight new developments in
the gastrointestinal protection strategy for CRD5, its evaluation in Yucatan
miniature pigs and planned subsequent clinical testing. In addition, the
company will present recent discovery and patent developments for novel second
generation synthetic compounds with exceptional activity to stimulate the
synthesis and secretion of HDL by the liver," said Dr. Daniel Sparks, Chief
Scientific Officer at Liponex. "Our discovery expertise has aided the
reformulation of our CRD5 and has yielded new drug candidates with great
promise to raise HDL levels."
    Bill Dickie, President and CEO of Liponex, further added, "The scientific
community is unanimous in the view that therapeutics to raise plasma HDL
levels will treat atherosclerosis and cardiovascular disease. We expect CRD5
and related second generation molecules to be important drugs in this arena."

    About Liponex

    Liponex is a biopharmaceutical company specializing in developing
products related to High Density Lipoprotein (HDL), often called "good
cholesterol". Its drug candidates relate to the various roles of HDL as a
transport vehicle, including removing excess cholesterol from the body,
delivering molecules to cells and removing unwanted materials from the body.
Liponex is listed on the TSX under the ticker "LPX". For more information on
Liponex, visit

    Certain of the statements contained in this press release contain
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Statements of
"belief" or "expectation" with respect to the our reformulation efforts, the
undertaking of future clinical trials for CRD5 and the efficacy of CRD5 and
second generation synthetic compounds in raising HDL levels, are based
primarily upon results derived to date from the Company's pre-clinical
research and development and its results from completed Phase I and Phase I/II
clinical trials. While the Company believes that it has reasonable scientific
basis upon which to make such statements, it is not possible to predict
whether a new therapeutic agent will be proven to be safe and/or effective in
humans. The Company cannot guarantee that it actually will achieve the plans,
intentions or expectation and undue reliance should not be placed on those
forward-looking statements. The Company does not expect to update
forward-looking statements continually as conditions change. Investors are
referred to the full discussion of risk factors associated with the Company's
business contained in the Company's periodic regulatory filings, which can be
found in the SEDAR database at

    %SEDAR: 00022196E

For further information:

For further information: Investor Relations, Michael Moore, The Equicom
Group Inc., (416) 815-0700 ext. 241,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890